Review
Immunology
Uday Raj Sharma, Akhila Nediyedath Rathnakaran, B. P. Prudhvi Raj, Gayathry Padinjakkara, Akanksh Das, Surendra Vada, Manjunatha P. Mudagal
Summary: Rheumatoid arthritis is an autoimmune inflammatory disorder characterized by joint destruction and symmetrical symptoms. Pregnancy has a positive effect on RA, with different hypotheses explaining this. Treatment options for RA include the use of DMARDs and NSAIDs.
INFLAMMOPHARMACOLOGY
(2021)
Review
Medicine, General & Internal
Mengduan Pang, Zhe Sun, Hongfeng Zhang
Summary: This meta-analysis compared the risk of all-cause mortality between biological/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) and non-b/tsDMARDs in patients with rheumatoid arthritis (RA). The results showed that compared to non-b/tsDMARDs, antitumor necrosis factor therapy was associated with an increased risk of mortality.
Article
Biotechnology & Applied Microbiology
Sajeev Kumar Babasahib, Roaddy Well Born, Nulgumnalli Manjunathaiah Raghavendra
Summary: In this study, the authors developed NAP and SULF ethosomes in hydrogel carrier, which showed stable and effective anti-inflammatory effects in vivo. The NAP-SULF ethosomes-hydrogel demonstrated sustained drug release and significant inhibition of inflammation, potentially serving as a novel approach for the treatment of RA.
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY
(2022)
Article
Rheumatology
Ahmad A. Sherbini, James M. Gwinnutt, Kimme L. Hyrich, Suzanne M. M. Verstappen
Summary: The study estimated the prevalence rates of AEs in RA patients starting MTX in the first year of treatment and found that factors such as female gender and alcohol consumption increased the odds of AEs, while older age, higher estimated glomerular filtration rate, and alcohol consumption were associated with lower reporting of haematological AEs.
Article
Rheumatology
Mohammad Mamun Khan, Shamim Ahmed, Md Kamrul Hasan Sajib, Abdullah All Morshed, Khandker Mahbub-Uz-Zaman, Syed Atiqul Haq
Summary: This study aimed to compare the effectiveness of tofacitinib and methotrexate (MTX) as first-line disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis (RA). The results showed that high-dose MTX (25 mg/week, subcutaneously) used in this study had similar therapeutic effects as tofacitinib in patients with established RA who were DMARD naive or had not received a therapeutic dose of DMARDs. However, there were differences in adverse effects between the two drugs.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Imke Redeker, Katinka Albrecht, Joern Kekow, Gerd Ruediger Burmester, Juergen Braun, Martin Schaefer, Angela Zink, Anja Strangfeld
Summary: The study compared the occurrence of herpes zoster in patients with rheumatoid arthritis undergoing different treatments, showing a higher risk associated with targeted synthetic and biologic DMARDs.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
S. M. Jung, K. -S. Park, K. -J. Kim
Summary: The study classified patients with RA into four clusters with distinct phenotypes through unsupervised clustering, with key features including sex, smoking, hypertension, and dyslipidaemia. Patients in Cluster 1, consisting of male smokers, were most likely to initiate bDMARDs by 30 months. High-risk patients for early initiation of bDMARDs were identified based on a combination of clinical parameters, suggesting potential usefulness for RA management.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
(2021)
Review
Immunology
Aayush Sehgal, Tapan Behl, Sukhbir Singh, Neelam Sharma, Mohammed Albratty, Hassan A. Alhazmi, Abdulkarim M. Meraya, Lotfi Aleya, Aditi Sharma, Simona Bungau
Summary: Rheumatoid arthritis is a chronic inflammatory disorder that leads to joint destruction and increased mortality. Cardiovascular disorders are a major cause of death in this condition. Endothelin may play an important role in the progression of the disease.
INFLAMMOPHARMACOLOGY
(2022)
Article
Rheumatology
Daniel Maunder, Philip M. Brown, Ben Barron-Millar, Dennis W. Lendrem, Najib Naamane, Jamie Macdonald, Xiao N. Wang, John D. Isaacs, Amy E. Anderson, Ann W. Morgan, Rachel E. Crossland, Sarah L. Mackie, Arthur G. Pratt
Summary: This study evaluated the potential of serum EV miRs as diagnostic and therapeutic biomarkers in early RA and found a novel potential mechanism by which MTX may exert its therapeutic effect in early RA.
Review
Rheumatology
Alexandre Sepriano, Andreas Kerschbaumer, Sytske Anne Bergstra, Josef S. Smolen, Desiree van der Heijde, Roberto Caporali, Christopher J. Edwards, Patrick Verschueren, Savia de Souza, Janet Pope, Tsutomu Takeuchi, Kimme Hyrich, Kevin L. Winthrop, Daniel Aletaha, Tanja Stamm, Jan W. Schoones, Robert B. M. Landewe
Summary: This study conducted a systematic literature review (SLR) to evaluate the safety of synthetic and biological disease-modifying antirheumatic drugs (DMARDs) for the management of rheumatoid arthritis (RA). The results indicated that bDMARDs were associated with an increased risk of serious infections compared to csDMARDs, while JAK inhibitors (JAKi) showed higher risk of herpes zoster infections. The risks of malignancies, major adverse cardiovascular events (MACE), and venous thromboembolism (VTE) were similar among different treatments.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Jeffrey A. Sparks, Zachary S. Wallace, Andrea M. Seet, Milena A. Gianfrancesco, Zara Izadi, Kimme L. Hyrich, Anja Strangfeld, Laure Gossec, Loreto Carmona, Elsa F. Mateus, Saskia Lawson-Tovey, Laura Trupin, Stephanie Rush, Patricia Katz, Gabriela Schmajuk, Lindsay Jacobsohn, Leanna Wise, Emily L. Gilbert, Ali Duarte-Garcia, Maria O. Valenzuela-Almada, Guillermo J. Pons-Estel, Carolina A. Isnardi, Guillermo A. Berbotto, Tiffany Y-T Hsu, Kristin M. D'Silva, Naomi J. Patel, Lianne Kearsley-Fleet, Martin Schafer, Sandra Lucia Euzebio Ribeiro, Samar Al Emadi, Liselotte Tidblad, Carlo Alberto Scire, Bernd Raffeiner, Thierry Thomas, Rene-Marc Flipo, Jerome Avouac, Raphaele Seror, Miguel Bernardes, Maria Margarida Cunha, Rebecca Hasseli, Hendrik Schulze-Koops, Ulf Mueller-Ladner, Christof Specker, Viviane Angelina de Souza, Licia Maria Henrique da Mota, Ana Paula Monteiro Gomides, Philippe Dieude, Elena Nikiphorou, Vanessa L. Kronzer, Namrata Singh, Manuel F. Ugarte-Gil, Beth Wallace, Akpabio Akpabio, Ranjeny Thomas, Suleman Bhana, Wendy Costello, Rebecca Grainger, Jonathan S. Hausmann, Jean W. Liew, Emily Sirotich, Paul Sufka, Philip C. Robinson, Pedro M. Machado, Jinoos Yazdany
Summary: This study investigated the baseline use of biologic or targeted synthetic disease-modifying antirheumatic drugs and COVID-19 outcomes in patients with rheumatoid arthritis. The results showed that patients treated with rituximab or Janus kinase inhibitors were associated with worse COVID-19 severity, emphasizing the need for prioritizing risk mitigation strategies for these individuals.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Rheumatology
Paul Studenic, Daniel Aletaha, Maarten de Wit, Tanja A. Stamm, Farideh Alasti, Diane Lacaille, Josef S. Smolen, David T. Felson
Summary: This study aimed to externally validate a revised Boolean remission criteria using a higher patient global assessment (PtGA) threshold and validate the provisionally endorsed index-based criteria. The results showed that using the higher PtGA threshold increased the proportion of patients classified as achieving remission under the "Boolean2.0" criteria, improved agreement with index-based criteria, and did not compromise predictive value for radiographic or functional outcomes. The study findings were endorsed by ACR and EULAR.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Pharmacology & Pharmacy
Yun-Kyoung Song, Gaeun Lee, Jinseub Hwang, Ji-Won Kim, Jin-Won Kwon
Summary: In Korean patients with rheumatoid arthritis (RA) without cardiovascular disease (CVD), Janus kinase (JAK) inhibitors were not associated with major adverse cardiovascular events (MACEs) compared to biologic disease-modifying antirheumatic drugs (bDMARDs).
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Susan Siyu Wang, Myles J. Lewis, Costantino Pitzalis
Summary: Rheumatoid arthritis (RA) is a complex disease with heterogeneity in disease severity and treatment response. Current prediction methods for treatment response have limitations, and genetics and environmental factors alone cannot fully explain the differences between patients. Recent studies have shown that DNA methylation plays a role in the pathogenesis and progression of RA, and specific DNA methylation profiles in the blood may serve as predictive biomarkers. This review examines the evidence for DNA methylation signatures in treatment response and discusses the potential for future progress in this area.
Article
Immunology
Zahra Mahmoudi, Negin Karamali, Seyed Askar Roghani, Shirin Assar, Mehran Pournazari, Parviz Soufivand, Farhad Salari, Alireza Rezaiemanesh
Summary: The study investigated the gene expression levels of MALAT1, H19, miR-199a-5p, and miR-1-3p in RA patients. MALAT1 and H19 may serve as potential biomarkers for distinguishing RA patients from controls.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Rheumatology
Eldin Dzubur, Carine Khalil, Christopher V. Almario, Benjamin Noah, Deeba Minhas, Mariko Ishimori, Corey Arnold, Yujin Park, Jonathan Kay, Michael H. Weisman, Brennan M. R. Spiegel
ARTHRITIS CARE & RESEARCH
(2019)
Letter
Rheumatology
Jonathan Kay, Thomas Doerner, Paul Emery, Tore K. Kvien, Ferdinand C. Breedveld
ANNALS OF THE RHEUMATIC DISEASES
(2020)
Review
Rheumatology
Kevin L. Winthrop, Michael E. Weinblatt, Mary K. Crow, Gerd R. Burmester, Philip J. Mease, Alexander K. So, Vivian Bykerk, Ronald F. Van Vollenhoven, Maxime Dougados, Jonathan Kay, Xavier Mariette, Joachim Sieper, Fritz Melchers, Bruce N. Cronstein, Ethan Shevach, Ferdinand C. Breedfeld, Joachim Kalden, Josef S. Smolen, Daniel E. Furst
ANNALS OF THE RHEUMATIC DISEASES
(2019)
Editorial Material
Medicine, General & Internal
Jonathan Kay
JOURNAL OF INTERNAL MEDICINE
(2019)
Article
Rheumatology
Atul Deodhar, Lianne S. Gensler, Jonathan Kay, Walter P. Maksymowych, Nigil Haroon, Robert Landewe, Martin Rudwaleit, Stephen Hall, Lars Bauer, Bengt Hoepken, Natasha de Peyrecave, Brian Kilgallen, Desiree van der Heijde
ARTHRITIS & RHEUMATOLOGY
(2019)
Editorial Material
Rheumatology
Jonathan Kay, Sergio Schwartzman
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
(2019)
Editorial Material
Rheumatology
Jonathan Kay
NATURE REVIEWS RHEUMATOLOGY
(2020)
Article
Rheumatology
Joshua F. Baker, Charles E. Leonard, Vincent Lo Re, Michael H. Weisman, Michael D. George, Jonathan Kay
ARTHRITIS & RHEUMATOLOGY
(2020)
Article
Rheumatology
Rene Westhovens, William F. C. Rigby, Desiree van der Heijde, Daniel W. T. Ching, William Stohl, Jonathan Kay, Arvind Chopra, Beatrix Bartok, Franziska Matzkies, Zhaoyu Yin, Ying Guo, Chantal Tasset, John S. Sundy, Angelika Jahreis, Neelufar Mozaffarian, Osvaldo Daniel Messina, Robert B. M. Landewe, Tatsuya Atsumi, Gerd R. Burmester
Summary: The study showed that Filgotinib significantly improved symptoms and physical function in active RA patients treated in combination with MTX, while FIL200 monotherapy did not show a significant advantage in ACR20 response rate compared to MTX.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Rheumatology
Catherine E. Dube, Kate L. Lapane, Katarina A. Ferrucci, Ariel L. Beccia, Sara K. Khan, Esther Yi, Jonathan Kay, Kristine A. Kuhn, Alexis Ogdie, Shao-Hsien Liu
Summary: Patients with axial spondyloarthritis (axSpA) often suffer from symptoms for over 13 years before diagnosis, leading to psychological distress and healthcare burden. Many patients described significant suffering due to meandering and frustrating diagnostic journeys, sometimes being perceived as somaticizing or crazy. Further research on early disease experiences of axSpA patients is needed.
RHEUMATOLOGY AND THERAPY
(2021)
Article
Multidisciplinary Sciences
Divya Shridharmurthy, Kate L. Lapane, Sara Khan, Esther Yi, Jonggyu Baek, Jonathan Kay, Shao-Hsien Liu
Summary: The 6-item SpA-SED screening tool designed to identify potential cases of axSpA was found to have good test-retest reliability and high internal consistency.
Article
Rheumatology
Jonathan Kay, Amy E. Bock, Muhammad Rehman, Wuyan Zhang, Min Zhang, Noriko Iikuni, Daniel F. Alvarez
Summary: This study explores the potential use of multibiomarker disease activity (MBDA) score in supporting biosimilarity assessments. The results show that MBDA scores can provide objective, quantitative evidence of biosimilarity.
Article
Rheumatology
Shao-Hsien Liu, Divya Shridharmurthy, Kate L. Lapane, Catherine E. Dube, Ellen M. Gravallese, Jonathan Kay
Summary: Most participants in the study, regardless of axial or peripheral spondyloarthritis, were well-educated non-Hispanic White men, with about 40% meeting US Department of Health and Human Services physical activity recommendations. While attitudes and beliefs towards exercise were similar among different disease types, those with axial disease showed greater concerns regarding discomfort and joint injuries. Participants with axial spondyloarthritis spent less time in light and moderate activities compared to those with peripheral disease.
JOURNAL OF RHEUMATOLOGY
(2021)
Article
Rheumatology
Jonathan Kay, Masayoshi Harigai, Josh Rancourt, Christina Dickson, Thomas Melby, Maher Issa, Inmaculada de la Torre, Yoshitaka Isaka, Anabela Cardoso, Chadi Saifan, Edward C. Keystone, Ronald F. van Vollenhoven, Jon T. Giles, Tom W. J. Huizinga, Joel M. Kremer
Article
Rheumatology
Woojin Joo, Christopher V. Almario, Mariko Ishimori, Yujin Park, Alma Jusufagic, Benjamin Noah, Lianne S. Gensler, R. Swamy Venuturupalli, Jonathan Kay, Michael H. Weisman, Brennan M. R. Spiegel
ACR OPEN RHEUMATOLOGY
(2020)